Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations.

Full transcript - Recursion Pharmaceuticals Inc (RXRX) Q2 2025: Chris Gibson, Co-Founder and CEO, Recursion Pharmaceuticals: Recursion’s q two twenty twenty five earnings call.

Recursion Pharmaceuticals is expected to provide updates regarding the clinical-stage pipeline programs on its second-quarter earnings call.

SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. RXRX) on Tuesday reported a loss of $171.9 million in its second quarter. On a per-share basis, the Salt Lake City-based company said it had ...

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Tuesday reported a loss of $171.9 million in its second quarter.

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Tuesday reported a loss of $171.9 million in its second quarter.

SALT LAKE CITY (AP) — SALT LAKE CITY (AP) — Recursion Pharmaceuticals Inc. (RXRX) on Tuesday reported a loss of $171.9 million in its second quarter.

The company also collaborated with NVIDIA Corporation, the global leader in visual computing technologies, to develop a next-generation platform for the creation of novel therapies. Recursion ...

J. D. Jobson, Bob Korkie, Statistical Inference in Two-Parameter Portfolio Theory with Multiple Regression Software, The Journal of Financial and Quantitative Analysis, Vol. 18, No. 2 (Jun., 1983), pp ...